Cronos Group Inc
CRON: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$8.70 | Skpbc | Qchnkfp |
Cronos Remains Years Away From Positive Adjusted EBITDA, but Remains Buoyed by a Hefty Cash Balance
Business Strategy and Outlook
Cronos Group cultivates and sells cannabis predominantly in Canada and hemp-derived CBD in the U.S. but also participates in the global medical cannabis market.